Time - and concentration - dependent effects of resveratrol on miR 15a and miR16-1 expression and apoptosis CCRF-CEM acute lymphoblastic leukemia cell line

Asian Pacific Journal of Cancer Prevention

Volumn 16, Issue 15, 2015, Pages 6463-6468

  Azimi, Ako ^a   Hagh, Majid Farshdousti ^a   Talebi, Mehdi ^a   Yousefi, Bahman ^a   Hossein Pour Feizi, Abbas Ali ^a   Baradaran, Behzad ^a   Movassaghpour, Ali Akbar ^a   Shamsasenjan, Karim ^a   Khanzedeh, Taghi ^a   Ghaderi, Abdol Hasan ^a   Heydarabad, Milad Zadi ^a  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

ALL; Apoptosis; MiR 15a; MiR 16 1; Resveratrol

Indexed keywords

ANTINEOPLASTIC AGENT; MICRORNA; MIRN15 MICRORNA, HUMAN; MIRN16 MICRORNA, HUMAN; RESVERATROL; STILBENE DERIVATIVE;

APOPTOSIS; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION; GENETICS; HUMAN; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TIME FACTOR; TUMOR CELL LINE; UPREGULATION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; HUMANS; MICRORNAS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; STILBENES; TIME FACTORS; UP-REGULATION;

EID: 84944463738     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2015.16.15.6463     Document Type: Article

References (51)

1. Ambros V (2004). The functions of animal microRNAs. Nature, 431, 350-5.
2. Burdelya L, Kujawski M, Niu G, et al (2005). Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects. J Immunol, 174, 3925-31.
3. Bartel DP (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 116, 281-97.
4. Bernhard D, Tinhofer I, Tonko M, et al (2000). Resveratrol causes arrest in the S-phase prior to Fas-independent apoptosis in CEM-C7H2 acute leukemia Cells. Cell Death Differ, 7, 834-842.
5. Chin YT, Hsieh MT, Yang SH, et al(2014). Anti-proliferative and gene expression actions of resveratrol in breast cancer cells in vitro. Oncotarget, 5, 12891-907.
6. Cullberg KB, Foldager CB, Lind M, Richelsena B, Pedersena SB (2014). Inhibitory effects of resveratrol on hypoxia-induced inflammation in 3T3-L1 adipocytes and macrophages. J Funct Foods, 7, 171-79.
7. Calin GA, Cimmino A, Fabbri M, et al. (2008). MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci U S A, 105, 5166-71.
8. Chivukula RR, Mendell JT (2008). Circular reasoning: microRNAs and cellcycle control. Trends Biochem Sci, 33, 474-81.
9. Cecchinato V, Chiaramonte R, Nizzardo M, et al (2007). Resveratrol-induced apoptosis in human T-cell acute lymphoblastic leukaemia MOLT-4 cells. Biochemical Pharmacol, 74, 1568-74.
10. Cui J, Fu H, Feng J, et al (2007). The construction of miRNA expression library for human. Progr. Biochem. Biophys, 34, 389-94.
11. Cimmino A, Calin GA, Fabbri M, et al (2005). MiR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A, 102, 13944-49.
12. Calin GA, Dumitru CD, Shimizu M, et al (2002). Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A, 99, 15524-29.
13. Clement MV, Hirpara JL, Chawdhury SH, Pervaiz S (1998). Chemopreventive agent resveratrol, a natural product derived from grapes, triggers CD95 signaling-dependent apoptosis in human tumor cells. Blood, 92, 996-1002.
14. Della RF, Cucciolla V, Borriello A, et al (1998). Resveratrol arrests the cell division cycle at S/G2 phase transition. Biochem Biophys Res Commun, 250, 53-8.
15. Dirks W, Schone S, Uphoff C, et al (1997). Expression and function of CD95 (FAS/APO-1) in leukaemia-lymphoma tumour lines. Br J Haematol, 96, 584-593.
16. Estrov Z, Shishodia S, Faderl S, et al (2003). Resveratrol blocks interleukin-1h-induced activation of the nuclear transcription factor NF-nB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells. Blood, 102, 987-95.
17. Fouad MA, Agha AM, Merzabani MM, Shouman SA (2013). Resveratrol inhibits proliferation, angiogenesis and induces apoptosis in colon cancer cells: calorie restriction is the force to the cytotoxicity. Hum Exp Toxicol, 32, 1067-80.
18. Fulda S (2010). Resveratrol and derivatives for the prevention and treatment of cancer. Drug Discov Today, 15, 757-65.
19. Fremont L (2000). Biological effects of resveratrol. Life Sciences, 66, 663-73.
20. Fontecave M, Lepoivre M, Elleingand E, Gerez C, Guittet O (1998). Resveratrol, a remarkable inhibitor of ribonucleotide reductase. FEBS Lett, 421, 277-9.
21. Guang-Hua F, Zhong-Ming W, Xi Y, et al (2014). Resveratrol inhibits oesophageal adenocarcinoma cell proliferation via AMP-activated protein kinase signaling. Asian Pac J Cancer Prev, 15, 677-82.
22. Hai-Tao Y, Qing-Zhong T, Luan G, et al (2013). In vitro and in vivo evaluation of the antitumor efficiency of resveratrol against lung cancer. Asian Pac J Cancer Prev, 14, 1703-06.
23. He L, Hannon GJ (2004). MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet, 5, 522-31.
24. Hsieh TC, Juan G, Darzynkiewicz Z, Wu JM (1999). Resveratrol increases nitric oxide synthase, induces accumulation of p53 and p21(WAF1/CIP1), and suppresses cultured bovine pulmonary artery endothelial cell proliferation by perturbing progression through S and G2. Cancer Res, 59, 2596-601.
25. Inui M, Martello G, Piccolo S (2010). MicroRNA control of signal transduction. Nat Rev Mol Cell Biol, 11, 252-63.
26. Jie-Yu F, Zhi-Hua L, Qiang L, et al (2012). Resveratrol affects protein kinase C activity and promotes apoptosis in human colon carcinoma cells. Asian Pac J Cancer Prev, 13, 6017-22.
27. Juan ME, Alfaras I, Planas JM (2012). Colorectal cancer chemoprevention by trans-resveratrol. Pharmacol Res, 65, 584-91.
28. Keitaro H, Nobuyoshi K (2012). Stilbene derivatives promote Ago 2-dependent tumour-suppressive microRNA activity. Sci Rep, 2, 314.
29. Lephart ED, Sommerfeldt JM, Andrus MB (2014). Resveratrol: Influences on gene expression in human skin. J Funct Foods, 10, 377-84.
30. Liu B, Zhou Z, Zhou W, et al (2014). Resveratrol inhibits proliferation in human colorectal carcinoma cells by inducing G1/S-phase cell cycle arrest and apoptosis through caspase/cyclin-CDK pathways. Mol Med Rep, 10, 1697-702.
31. Liu ML, Zhang SJ (2014). Effects of resveratrol on the protein expression of survivin and cell apoptosis in human gastric cancer cells, J Buon, 19, 713-17.
32. Lin CY, Hsiao WC, Wright DE, et al (2013). Resveratrol activates the histone H2B ubiquitin ligase, RNF20, in MD A-MB-231 breast cancer cells. J Funct Foods, 5, 790-800.
33. Lewis BP, Burge CB, Bartel DP (2005). Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are micro-RNA targets. Cell, 120, 15-20.
34. Lin MT, Yen ML, Lin CY, Kuo ML (2003). Inhibition of vascular endothelial growth factor-induced angiogenesis by resveratrol through interruption of Src-dependent vascular endothelial cadherin tyrosine phosphorylation. Mol Pharmacol, 64, 1029-36.
35. Niu G, Wright KL, Ma Y, et al (2005). Role of Stat3 in regulating p53 expression and function. Mol Cell Biol, 25, 7432-40.
36. Ofir M, Hacohen D, Ginsberg D (2011). miR-15 and miR-16 are direct transcriptional targets of E2F1 that Limit E2F-induced proliferation by targeting cyclin E. Mol Cancer Res, 9, 440-7.
37. Pallares V, Calay D, Cedo L, et al (2012). Enhanced antiinflammatory effect of resveratrol and epa intreated endotoxin-activated raw 256.7 macrophages. Br J Nutr, 14, 1562-73.
38. Panaro MA, Carofiglio V, Acquafredda A, Cavallo P, Cianciulli A (2012). Anti-inflammatory effects of resveratrol occur via inhibition of lipopolysaccharide-induced NF-kB activation in Caco-2 and SW480 human colon cancer cells. Br J Nutr, 108, 1623-32.
39. Pui C-H, Robison LL, Look AT (2008). Acute lymphoblastic leukaemia. Lancet, 371, 1030-43.
40. Sevinc S U, Sefa C, Ersin G, et al (2013). Anticancer effects of thymoquinone, caffeic acid phenethyl ester and resveratrol on A549 Non-small cell lung cancer cells exposed to benzo(a)pyrene. Asian Pac J Cancer Prev, 14, 6159-64.
41. Subash CG, Ramaswamy K, Simone R, Ji HK, Bharat BA (2011). Chemosensitization of tumors by resveratrol. Ann N Y Acad Sci, 1215, 150-60.
42. Stanulla M, Schrappe M (2009). Treatment of childhood acute lymphoblastic leukemia. Semin Hematol, 46, 52-63.
43. Signorelli P, Ghidoni R (2005). Resveratrol as an anticancer nutrient: molecular basis, open question and promises. J Nutr Biochem, 16, 449-66.
44. Surh YJ, Hurh YJ, Kang JY, et al (1999). Resveratrol. an antioxidant present in red wine, induces apoptosis in human promyelocytic leukemia (HLA60) cells. Cancer Letters, 140, 1-10.
45. Subbaramaiah K, Chung WJ, Michaluart P, et al (1998). Resveratrol inhibits cyclooxygenase2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J Biol Chem, 273, 21875-82.
46. Tsan MF, White JE, Maheshwari JG, Bremner TA, Sacco J (2000). Resveratrol induces fas signaling-independent apoptosis in THP-1 human monocytic leukemia cells. Br J Haematol, 109, 405-12.
47. Ulasli SS, Celik S, Gunay E, et al (2013). Anticancer effects of thymoquinone, caffeic acid phenethyl ester and resveratrol on A549 non-small cell lung cancer cells exposed to benzo(a) pyrene. Asian Pac J Cancer Prev, 14, 6159-64.
48. Xin-pin Wu, Min Xiong, Cheng-shan Xu, et al (2015). Resveratrol induces apoptosis of human chronic myelogenous leukemia cells in vitro through p38 and JNK-regulated H2AXphosphorylation. Acta Pharmacol Sin, 36, 353-61.
49. Yang Q, Wang B, Zang W, et al (2013). Resveratrol inhibits the growth of gastric cancer by inducing G1 phase arrest and senescence in a Sirt1-dependent manner. PLoS One, 8, 70627.
50. Yu XM, Jaskula-Sztul R, Ahmed K, et al (2013). Resveratrol induces differentiation markers expression in anaplastic thyroid carcinoma via activation of notch1 signaling and suppresses cell growth. Mol Cancer Ther, 12, 1276-87.
51. Yu R, Hebbar V, Kim DW, et al (2001). Resveratrol inhibits phorbol ester and UV-induced activator protein 1 activation by interfering with mitogen-activated protein kinase pathways. Mol Pharmacol, 60, 217-24.